Alpha-Lipoic Acid (ALA) for Stage IV Cancer
Also known as: ALA, Thioctic acid, R-lipoic acid
ALA's pro-oxidant effect at high doses selectively targets cancer cells with elevated ROS, while protecting normal tissue at physiological levels.
Mechanism of Action
At high IV doses, ALA generates ROS preferentially in cancer cells (which have higher baseline oxidative stress), triggering apoptosis. It inhibits NF-κB, reduces pyruvate dehydrogenase kinase activity, and modulates insulin/IGF-1 signaling relevant to cancer metabolism.
General mechanism: Universal antioxidant and mitochondrial cofactor. Regenerates other antioxidants, chelates metals, enhances pyruvate dehydrogenase activity.
Current Evidence
Case reports and small trials in pancreatic and colon cancer show tolerability. IV ALA protocols used in integrative oncology. Randomized controlled data limited.
Clinical Status: Phase I/II. IV protocols in integrative oncology. No FDA approval for cancer.
Safety Profile
Very safe orally. IV use requires medical supervision. Hypoglycemia risk in diabetics. Rare: autoimmune insulin syndrome in susceptible individuals.
Key Research Questions
- What is the therapeutic window between anti-cancer and cytoprotective ALA doses?
- Can ALA enhance chemotherapy efficacy through NF-κB suppression?